SCHEMBL4851005

SCHEMBL4851005

COP(=O)(OC)C(=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.53
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
SRD5A2 P31213 1/20 0.45
MAPK1 P28482 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
PTGS2 P35354 2/20 0.42
POLB P06746 2/20 0.42
ELANE P08246 1/20 0.42
CNR1 P21554 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11142056 0.96 HPGD (0.59) HPGDCES2CES1SRD5A2MAPK1
SCHEMBL776346 0.82 ALDH1A1 (0.54) HPGDCES2CES1SRD5A2ALDH1A1
SCHEMBL11411158 0.80 CA1 (0.55) MAPK1TSHRALDH1A1MAPTL3MBTL1
SCHEMBL4610734 0.80 CES2 (0.57) HPGDCES2CES1MAPK1ALOX15
SCHEMBL11515099 0.79 SMN1; SMN2 (0.49) HPGDCES2CES1SRD5A2MAPK1
SCHEMBL2989889 0.79 LMNA (0.53) HPGDCES2CES1SRD5A2ALOX15
SCHEMBL11456405 0.77 MAPT (0.52) HPGDMAPK1ALDH1A1LMNAMAPT
SCHEMBL11052337 0.77 HDAC1 (0.53) HPGDSRD5A2MAPK1ALOX15ALDH1A1
SCHEMBL10881925 0.76 ALOX15 (0.41) HPGDCES2CES1SRD5A2ALOX15
SCHEMBL11400421 0.74 MAPK1 (0.55) CES2CES1SRD5A2MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468359-B2 Compositions comprising oxophosphonate-based metalloproteinase inhibitors YISSUM RESEARCH DEVELPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) 2008-12-23 US disclosed
US-20060199787-A1 COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-09-07 US disclosed
US-7101864-B1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-09-05 US disclosed
EP-0042567-A2 Photopolymerisable mixtures with aroylphosphonic acid esters as photoinitiators BAYER AG (DE) 1981-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199787-A1 COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS ENPP1, MMP1, MMP9 HPGD 394/4885CES2 1855/4885CES1 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.